These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 16167079

  • 1. Proton beam therapy and iris neovascularisation in uveal melanoma.
    Boyd SR, Gittos A, Richter M, Hungerford JL, Errington RD, Cree IA.
    Eye (Lond); 2006 Jul; 20(7):832-6. PubMed ID: 16167079
    [Abstract] [Full Text] [Related]

  • 2. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma.
    Detorakis ET, Engstrom RE, Wallace R, Straatsma BR.
    Ophthalmology; 2005 Mar; 112(3):505-10. PubMed ID: 15745782
    [Abstract] [Full Text] [Related]

  • 3. Proton beam therapy for iris melanomas.
    Lumbroso-Le Rouic L, Delacroix S, Dendale R, Levy-Gabriel C, Feuvret L, Noel G, Plancher C, Nauraye C, Garcia P, Calugaru V, Asselain B, Desjardins L.
    Eye (Lond); 2006 Nov; 20(11):1300-5. PubMed ID: 16294207
    [Abstract] [Full Text] [Related]

  • 4. Proton beam therapy for iris melanoma: a review of 15 cases.
    Rundle P, Singh AD, Rennie I.
    Eye (Lond); 2007 Jan; 21(1):79-82. PubMed ID: 16410818
    [Abstract] [Full Text] [Related]

  • 5. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
    Krohn J, Monge OR, Skorpen TN, Mørk SJ, Dahl O.
    Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
    [Abstract] [Full Text] [Related]

  • 6. Conservation treatment of the eye: Conformal proton reirradiation for recurrent uveal melanoma.
    Marucci L, Lane AM, Li W, Egan KM, Gragoudas ES, Adams JA, Collier JM, Munzenrider JE.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1018-22. PubMed ID: 16376492
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.
    Yeung SN, Paton KE, Waite C, Maberley DA.
    Can J Ophthalmol; 2010 Jun 15; 45(3):269-73. PubMed ID: 20379286
    [Abstract] [Full Text] [Related]

  • 8. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas.
    Sahin A, Kiratli H, Tezel GG, Soylemezoglu F, Bilgic S.
    Ophthalmic Res; 2007 Jun 15; 39(1):40-4. PubMed ID: 17164576
    [Abstract] [Full Text] [Related]

  • 9. Ocular complications after iodine brachytherapy for large uveal melanomas.
    Puusaari I, Heikkonen J, Kivelä T.
    Ophthalmology; 2004 Sep 15; 111(9):1768-77. PubMed ID: 15350335
    [Abstract] [Full Text] [Related]

  • 10. Proton beam radiotherapy of iris melanoma.
    Damato B, Kacperek A, Chopra M, Sheen MA, Campbell IR, Errington RD.
    Int J Radiat Oncol Biol Phys; 2005 Sep 01; 63(1):109-15. PubMed ID: 16111578
    [Abstract] [Full Text] [Related]

  • 11. Posterior uveal melanoma in young patients treated with proton beam therapy.
    Vavvas D, Kim I, Lane AM, Chaglassian A, Mukai S, Gragoudas E.
    Retina; 2010 Sep 01; 30(8):1267-71. PubMed ID: 20224468
    [Abstract] [Full Text] [Related]

  • 12. Corneoscleral necrosis after episcleral Au-198 brachytherapy of uveal melanoma.
    Chaudhry IA, Liu M, Shamsi FA, Arat YO, Shetlar DJ, Boniuk M.
    Retina; 2009 Jan 01; 29(1):73-9. PubMed ID: 18728617
    [Abstract] [Full Text] [Related]

  • 13. Metastatic melanoma in the eye and orbit.
    Zografos L, Ducrey N, Beati D, Schalenbourg A, Spahn B, Balmer A, Othenin-Girard CB, Chamot L, Egger E.
    Ophthalmology; 2003 Nov 01; 110(11):2245-56. PubMed ID: 14597536
    [Abstract] [Full Text] [Related]

  • 14. Proton beam therapy for the treatment of uveal melanoma in Scotland.
    Macdonald EC, Cauchi P, Kemp EG.
    Br J Ophthalmol; 2011 Dec 01; 95(12):1691-5. PubMed ID: 21216794
    [Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.
    Boyd SR, Tan D, Bunce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA.
    Br J Ophthalmol; 2002 Apr 01; 86(4):448-52. PubMed ID: 11914216
    [Abstract] [Full Text] [Related]

  • 16. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
    Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S.
    Ophthalmology; 2005 May 01; 112(5):834-40. PubMed ID: 15878063
    [Abstract] [Full Text] [Related]

  • 17. Eye-wall resection.
    Char DH, Miller T, Crawford JB.
    Trans Am Ophthalmol Soc; 2000 May 01; 98():153-9; discussion 159-61. PubMed ID: 11190019
    [Abstract] [Full Text] [Related]

  • 18. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
    Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C, Delacroix S, Meyer A, Nauraye C, Mazal A, Mammar H, Garcia P, D'Hermies F, Frau E, Plancher C, Asselain B, Schlienger P, Mazeron JJ, Desjardins L.
    Int J Radiat Oncol Biol Phys; 2006 Jul 01; 65(3):780-7. PubMed ID: 16647221
    [Abstract] [Full Text] [Related]

  • 19. Uveal melanoma: management and outcome of patients with extraocular spread.
    Bellmann C, Lumbroso-Le Rouic L, Levy C, Plancher C, Dendale R, Sastre-Garau X, Asselain B, Desjardins L.
    Br J Ophthalmol; 2010 May 01; 94(5):569-74. PubMed ID: 19965816
    [Abstract] [Full Text] [Related]

  • 20. Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute.
    Höcht S, Bechrakis NE, Nausner M, Kreusel KM, Kluge H, Heese J, Heufelder J, Cordini D, Homeyer H, Fuchs H, Martus P, Foerster MH, Wiegel T, Hinkelbein W.
    Strahlenther Onkol; 2004 Jul 01; 180(7):419-24. PubMed ID: 15241529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.